Steen Meier Rønborg
Corporate Officer/Principal bij University of Copenhagen
Profiel
Steen Meier Rønborg is the founder of Alsensa ApS, which was founded in 2000.
He held the title of Administrative Director from 2010 to 2012.
Currently, he is a Principal at the University of Copenhagen.
Dr. Rønborg has an undergraduate and doctorate degree from the University of Copenhagen.
Actieve functies van Steen Meier Rønborg
Bedrijven | Functie | Begin |
---|---|---|
University of Copenhagen | Corporate Officer/Principal | 03-07-2009 |
Eerdere bekende functies van Steen Meier Rønborg
Bedrijven | Functie | Einde |
---|---|---|
Alsensa ApS
Alsensa ApS Miscellaneous Commercial ServicesCommercial Services Alsensa is a Danish-based Medical Device Research and Development, Design and Pilot-Scale manufacturing company. Alsensa's first Pilot-Scale product was the AQT all-in-one allergy testing device that will bring a new standard to antiquated Skin Prick Testing procedures. Alsensa has recently expanded the intended use of its primary product to include drug delivery applications. This product, currently under development stands to revolutionize the drug self-injection market. | Oprichter | 15-04-2010 |
Opleiding van Steen Meier Rønborg
University of Copenhagen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 1 |
---|---|
Alsensa ApS
Alsensa ApS Miscellaneous Commercial ServicesCommercial Services Alsensa is a Danish-based Medical Device Research and Development, Design and Pilot-Scale manufacturing company. Alsensa's first Pilot-Scale product was the AQT all-in-one allergy testing device that will bring a new standard to antiquated Skin Prick Testing procedures. Alsensa has recently expanded the intended use of its primary product to include drug delivery applications. This product, currently under development stands to revolutionize the drug self-injection market. | Commercial Services |